Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Several studies have shown that detection of PD-L1 protein on tumour cells before treatment correlates with a positive response to checkpoint inhibitors. However, some patients who seem to be PD ...

AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...

PD L1 is a protein known to reduce an immune cell's anti-cancer activity, and nivolumab works by blocking the receptor where PD L1 could bind to an immune cell, so preserving its anti-cancer activity.

Now researchers from The Rockefeller University have unearthed intriguing genetic evidence: a protein variant found only in humans that may have helped shape the emergence of spoken language.

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...